Physician profile
Michael Griswold
NPI 1972575694
$2,089.26
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $113 · 2021: $306 · 2022: $646 · 2023: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.45 | 2021-2023 | |
| Pfizer INC. | $290.67 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $201.48 | 2019-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $198.64 | 2019-2023 | Mounjaro, Jardiance |
| Amgen INC. | $165.53 | 2019-2023 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $154.76 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.55 | 2019-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $72.07 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $65.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $64.52 | 2019-2023 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $54.58 | 2019-2023 | Eliquis |
| Sumitomo Pharma America, INC. | $53.84 | 2023 | Gemtesa |
| Abbott Laboratories | $46.73 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $45.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $41.16 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.14 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.19 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.34 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $27.42 | 2021-2022 | |
| Amarin Pharma, INC. | $14.79 | 2020 | |
| Radius Health, INC. | $14.61 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.51 | 2023 | Rexulti |
| Exact Sciences Corporation | $14.18 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $12.69 | 2021 | |
| Allergan, INC. | $12.38 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.15 | 2021 | |
| Corium, LLC | $1.11 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Griswold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.